PoS 1
ePoster 01

Programm

• • ePoster
  • P001

  Effects of US-Guided trigger point interventions on ophthalmic artery doppler parameters and eye symptoms in patients with migraine and headache

  • Rostyslav Bubnov (Kyiv, UA)
• • ePoster
  • P002

  Pre-Treatment cephalic interictal allodynia predicts outcome of prophylactic treatment of chronic and episodic migraine patients with Galcanezumab: a prospective quantitative sensory testing study

  • Sait Ashina (Boston, US)
• • ePoster
  • P003

  Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine

  • Line Pickering Boserup (Valby, DK)
• • ePoster
  • P005

  A prokinetic effect of corydalis tuber and pahrbitidis semen extract (DA 9701) improves nausea and headache in migraine neurological disorders: a real world observational study

  • Manho Kim (Seoul, KR)
• • ePoster
  • P006

  Triptan failure in specialized headache care: cross-sectional data from the DMKG Headache Registry

  • Ruth Ruscheweyh (München, DE)
• • ePoster
  • P007

  Reduction in barbiturate prescription fills and quantity dispensed following initiation of rimegepant treatment: a real-world administrative claims study

  • Lucy Abraham (Tadworth, GB)
• • ePoster
  • P008

  BACT – Botulinum toxin A in frequent and chronic tension-type headache with the FollowTheSutures paradigm. A triple blind, randomized, placebo-controlled cross-over trial

  • Kristina Devik (Namsos, NO)
• • ePoster
  • P009

  OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine

  • Andreas Argyriou (Patras, GR)
• • ePoster
  • P010

  Predictors of response to fremanezumab in migraine patients with at least three previous preventive failures: post-hoc analysis of a prospective, multicenter, real-world Greek registry

  • Andreas Argyriou (Patras, GR)
• • ePoster
  • P011

  Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek registry

  • Andreas Argyriou (Patras, GR)
• • ePoster
  • P012

  Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post-hoc analysis of a prospective, multicenter, real-world Greek registry

  • Andreas Argyriou (Patras, GR)
• • ePoster
  • P013

  Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA. The RAMO study: early results

  • Danilo Antonio Montisano (Milano, IT)
  • Licia Grazzi (Milan, IT)
• • ePoster
  • P014

  Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis

  • Samita Giri (TRONDHEIM, NO)
• • ePoster
  • P015

  Real-world evidence for frequency of constipation with the use of anti-CGRP monoclonal antibodies in chronic migraine

  • Sena Uzun (Malmö, SE)
• • ePoster
  • P016

  Onabotulinum Toxin A (OnA) as a preventive treatment for non-migraine headaches: a retrospective analysis

  • Candela Nieves Castellanos (Valencia, ES)
• • ePoster
  • P017

  Real-World effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-european PEARL study

  • Messoud Ashina (Copenhagen, DK)
• • ePoster
  • P018

  Primary bilateral trigeminal neuralgia: controlling double trouble pain with onabotulinumtoxinA

  • Gonçalo Cabral (Lisboa, PT)
• • ePoster
  • LP001

  Suggested methodology for habituation deficit measurements in migraine patients undergoing preventive neuromodulatory treatment

  • Olga Sved (Tartu, EE)
• • ePoster
  • LP002

  Exposure, safety and effectiveness of 75 mg rimegepant administered as needed in the acute treatment of migraine among chinese adults: Interim analysis of a long-term safety study

  • Shengyuan Yu (Beijing, CN)